| Trial | Title | Study Record Detail | Phase | Sponsor/Colaborator |
|---|---|---|---|---|
| EMERGE | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | NCT01156753 | Phase II | Celldex Therapeutics |
| METRIC | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | NCT01997333 | Phase II | Celldex Therapeutics |
| A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma | NCT02302339 | Phase II | Celldex Therapeutics | |
| Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer | NCT00704158 | Phase I, Phase II | CuraGen Corporation | |
| A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | NCT00412828 | Phase I, Phase II | CuraGen Corporation | |
Note: As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc
Last Editorial Review: July 29, 2016
